AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page Visit acneandrosacea.org to Become an AARS Member and TABLE OF CONTENTS Donate Now on acneandrosacea.org/donate Industry News Mederma survey: America's got skin insecurities. ...................................................... 2 Our Officers Accure Acne seeks to raise up to $20 million through private placement offering ..... 2 J. Mark Jackson, MD AARS President New Medical Research Scientifically speaking: New directions in acne management, part 1. ........................ 3 Andrea Zaenglein, MD Tranexamic acid microinjections ................................................................................. 3 AARS President-Elect An increase in normetanephrine in hair follicles of acne lesions ................................ 4 Effects of ısotretinoin on the growth rate and thickness of the nail plate .................... 4 Joshua Zeichner, MD The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin .. 4 AARS Treasurer Efficacy and safety of non-surgical short-wave radiofrequency treatment ................. 5 Incidence and clinical implications of autoimmune thyroiditis ..................................... 5 Bethanee Schlosser, MD Topical 15% resorcinol is associated with high treatment satisfaction ....................... 6 AARS Secretary A novel azelaic acid formulation for the topical treatment of inflammatory rosacea ... 6 The effectiveness of galactomyces ferment filtrate ..................................................... 6 James Del Rosso, DO Director Clinical Reviews Emmy Graber, MD Efficacy of non-surgical monotherapies for hidradenitis suppurativa ......................... 7 Director Treatment challenges in adult female acne and future directions .............................. 7 Adalimumab induces a wound healing profile in patients ........................................... 8 Jonathan Weiss, MD Self-limited acne agminate-like granulomatous reaction ............................................ 8 Director Advances in oral isotretinoin therapy .......................................................................... 8 Boosting adherence and results with energy-based devices. .................................... 9 Stacey Moore Unraveling the heterogeneity of hidradenitis suppurativa with phenotype schema .... 9 Executive Director Use of botulinum toxin in treating rosacea .................................................................. 9 [email protected] Remote consultations for patients with hidradenitis suppurativa .............................. 10 Page 2 Industry News Mederma survey: America's got skin insecurities. Practical Dermatology, May 6, 2021. https://practicaldermatology.com/news/mederma-survey-skin-insecurities-have-major-impact-on-mental- health?c4src=search%3Afeed&utm_campaign=Practical%20Dermatology%20- %20Enewsletters&utm_medium=email&_hsmi=126575723&_hsenc=p2ANqtz- 8IAvXUSrlnzKcQ4zgwxFOz0UnD8WODhxK3G0DJzD1aAIFQdhDLtUx34IYfRNAYhwfMU7nJ0b9N8olOlj3PuTxRYy X2j5Vae4sfZPFQBJJkiS6O9mk&utm_content=126575723&utm_source=hs_email May is Mental Health Awareness month, and Mederma is unveiling their new "You Are More Than Your Scar" campaign to help people overcome skin insecurities and boost self esteem. One-third of Americans would not use their smart phone for a year if it meant they could have picture-perfect skin, according to a new survey from Mederma. That’s not all they would do for clear skin either, many would cancel Netflix for life eat only oatmeal for a year, give up their favorite food for life or skip sex for a year, the survey found. More than half of Americans avoid events altogether (pre-pandemic) instead of going through the hassle of dealing with skin issues and insecurities, and three in five respondents agreed that their skin has a big impact on their self-confidence and mental health. May is Mental Health Awareness month, and Mederma is unveiling their new "You Are More Than Your Scar" campaign to help people overcome skin insecurities and boost self esteem. Alongside the new campaign, Mederma has also unveiled new packaging design across their entire suite of products that is currently rolling out on shelves. "When we were creating our new 'You Are More Than Your Scar' campaign, it was inspiring to see that every scar has a story, and more importantly, people often fight silent battles with their marks and scars," says HRA Pharma America, President, Bradley Meeks, in a news release. "This survey has shown that skin insecurities affect everyone and feeling confident in the skin you're in has a connection to mental health." While the survey of 2,000 American adults revealed that skin imperfections have kept people from seeing family, going to birthday parties and even weddings, the survey also uncovered that some respondents already embrace their scars or have started to accept their insecurities – proving we are more than our scars. Download Reference Document Accure Acne seeks to raise up to $20 million through private placement offering. DermWire, Practical Dermatology, April 26, 2021. https://practicaldermatology.com/news/accure-acne-seeks-to-raise-up-to-20-million- through-private-placement-offering?c4src=topic%3Aacne%3Afeed&utm_campaign=Practical%20Dermatology%20- %20Enewsletters&utm_medium=email&_hsmi=126575723&_hsenc=p2ANqtz-89zUY2jvdCq6ReFH5b- VkRuRVE2eumJ_nJcx4Z80n66zZv8zWHdySHqTxNzYYBKiQt4JFiWgIyogEutA-aEpVD5_DE- LQfiXiPYF0PRGSkH7zKFFE&utm_content=126575723&utm_source=hs_email Accure Acne, Inc. has launched a private placement offering on the M-Vest platform to raise up to $20 Million. Building on the research of R. Rox Anderson, MD, Accure Co-Founder and Chief Scientific & Medical Officer, Accure has developed the Accure Laser System, an energy-based device that targets sebaceous glands. The company believes the technology utilizes a novel, proprietary treatment method that has been demonstrated on human tissue to damage sebaceous glands through selective photothermolysis, while sparing the surrounding epidermis from damage. In March 2020, Accure's exclusive manufacturing partner for the Accure Laser System, Quanta System S.p.A, received clearance for CE Mark certification. Accure believes this is the only 1726nm laser with CE Mark clearance for the treatment of moderate inflammatory acne. This investment involves a high degree of risk and should not be made by anyone who cannot afford to lose his or her entire investment. This investment is highly speculative and illiquid. The Subscription Agreement & Limited Liability Company Agreement is available online. American Acne & Rosacea Society (AARS) Hot Topics Volume: May 2021, Issue 1 Page 3 New Medical Research Scientifically speaking: New directions in acne management, part 1. Joel L. Cohen, MD; Diane Berson, MD; Linda Stein Gold, MD; and Emil Tanghetti, MD. Practical Dermatology, May 10, 2021. https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-new-directions-in-acne- management-part-1?c4src=topic%3Aacne%3Afeed&utm_campaign=Practical%20Dermatology%20- %20Enewsletters&utm_medium=email&_hsmi=126575723&_hsenc=p2ANqtz-9DA9UTqsZgFsH7_v7Dsfzc-qQ- ZkHAoBg7u63JvkXbiSbb1gSlgy-_m-ZxR8f_6a45wptkSd3YM_rWs1hkfAo9lq- P8yY6xISZVmD2Up5pJ3p3T04&utm_content=126575723&utm_source=hs_email The recognition that inflammation is at the heart of acne has led to changes in management approaches and better understanding of how treatments work. In the first of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, MD; Linda Stein Gold, MD; and Emil Tanghetti, MD about acne approaches, with a focus on the latest in topical interventions. They address hot topics, including bacterial resistance and variations in treatment response across different patient populations. Tranexamic acid microinjections: A novel treatment option for erythematotelangiectatic rosacea. J Cosmet Dermatol. 2021 May 10. doi: 10.1111/jocd.14209. Online ahead of print. Daadaa N, Litaiem N, Karray M, et al. https://pubmed.ncbi.nlm.nih.gov/33973361/ Background: Treatment options for erythematotelangiectatic rosacea (ETR) are still scarce. Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR. Aims: to evaluate the efficacy and safety of intradermal microinjections of TXA for ETR. Patients/methods: This was a retrospective study enrolling patients, treated with TXA intradermal microinjections for ETR, from January 2019 to February 2020. Response to treatment was assessed based on subjective symptoms, clinical photographs and the Investigator Global Assessment of Rosacea Severity Score (IGA-RSS). Results: Six patients were included. The mean number of monthly intradermal TXA microinjections was 5.1±1.3. The mean decrease of IGA-RSS was 2.4±0.5. Local side effects, mainly transient erythema and swelling, were noticed in three cases. No systemic effects were noted. Clinical improvement, in respondent patients, lasted after 3 months of follow-up. Conclusion: Intradermal TXA microinjections is a safe and effective treatment option for ETR. The optimal number of monthly sessions has yet to be determined. American Acne & Rosacea Society (AARS) Hot Topics Volume: May 2021, Issue 1 Page 4 An increase in normetanephrine in hair follicles of acne lesions through the sympatho-adrenal medullary system in acne patients with anxiety. Mizuno K, Sakaue H, Kohsaka K, et al. J Dermatol.